Portland, Oregon –– Sedia Biosciences Corporation of Portland, Oregon will be presenting its first public results of a new rapid point-of-care HIV incidence assay at the upcoming 20th International AIDS Conference in Melbourne Australia, July 21-25, 2014.  The new assay is expected to augment Sedia’s suite of commercial HIV incidence products and further establish Sedia’s leadership in the development and manufacture of laboratory assays to monitor the epidemic around the world.   The presentation, given as a scientific poster, is entitled “Characterization of a rapid HIV-1 incidence assay based on a CDC-developed multi-subtype antigen in a commercial HIV lateral flow assay format.”

The poster presentation (Poster # WEPE105) will be hosted by Sedia’s Director of Product Support and Technical Services, Paul Smith from 12:30 pm to 2:30 pm on Wednesday, July 23, 2014.  Mr. Smith stated “This is an exciting new concept incorporating Sedia’s rapid test technology with components of the Sedia™ HIV-1 LAg-Avidity EIA to bring HIV incidence testing to resource limited settings.  We are currently working with the Centers for Disease Control and Prevention (CDC) to fully develop this as a new commercial product.”  The new assay incorporates technology developed by both the CDC and Sedia.  Co-authors for the presentation are Dr. Ronald Mink, President and Chief Science Officer, and Stephen Piacentini, Director of Assay Development, who are also attending the conference, and Mimi Jackson, Research Assistant.  The poster will also be available for general viewing all day, Wednesday, from 9:00 am to 6:00 pm.

Sedia Biosciences will also be exhibiting its products at the Commercial Exhibition Hall of the International AIDS Conference from Sunday July 20 through Thursday July 24.  Dr. Mink stated “This conference presents a unique and important opportunity for Sedia to not only present its HIV products to scientists, policymakers and public health officials working in that field, but to also make them aware of our other products and technologies that can further advance their scientific efforts.  We look forward to seeing many of our old friends that have partnered with Sedia over the years, but also to making new friends and building new relationships.”

The International AIDS Conference, which runs from July 20 to 25, 2014, is the premier meeting for those working in the field of HIV, including scientists, policymakers, people living with HIV and others dedicated to ending the epidemic. The conference brings together researchers from around the world to share and learn of new scientific advances in the field.  The Conference is expected to include over 14,000 delegates from nearly 200 countries.  Additional information is available at www.aids2014.org.

About Sedia Biosciences Corporation:

Sedia Biosciences Corporation (www.sediabio.com) is a U.S.-based healthcare company focused on the development and commercialization of novel in vitro diagnostic and epidemiological tests. The company is dedicated to advancing access to medical care by developing innovative diagnostic and monitoring products that enable more cost effective and expanded testing for infectious diseases and other conditions. Based in Portland, Oregon, Sedia develops, manufactures, licenses and sells in vitro diagnostic and epidemiological tests as well as specimen collection devices.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.  Those statements include statements regarding the intent, belief or current expectations of the Company and its management.  Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties.  Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company’s ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability.  The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events.